Dr. Qu Zhican, Chairman of Nanolattix, Attends the 10th China BioMed Innovation and Investment Conference and Delivers Keynote Speech
Release time:
2025-11-04
From October 26 to 27, 2025, the 10th China BioMed Innovation and Investment Conference was grandly held in Nanjing, bringing together leading enterprises and top minds in the industry to focus on the latest developments in global pharmaceutical R&D. Dr. Qu Zhican, Chairman of Nanolattix, was invited to attend and deliver a keynote speech, providing cutting-edge insights into the field of innovative drugs.
On October 27, in a keynote speech titled "Creating Novel Anti-Cancer Drugs: Antibody-Conjugated RDC/ADC," Dr. Qu Zhican delved into the innovative pathways of Antibody-Drug Conjugates (ADC) and Radiopharmaceutical Drug Conjugates (RDC). RDC drugs integrate life sciences, medicine, and nuclear technology, representing a critical direction for theranostics. Nanolattix's self-developed, first-in-class innovative drug RT01 precisely delivers lutetium-177 radionuclides via targeted antibodies, offering dual functions of therapy and imaging tracking. It has demonstrated exceptional anti-tumor efficacy and favorable safety in preclinical studies, showing immense application potential.
The China BioMed Innovation and Investment Conference focuses on discussing global pharmaceutical innovation trends and serves as a collaborative platform for "government, industry, academia, research, application, and capital." It has become a bellwether for domestic pharmaceutical innovation and investment. During the conference, Dr. Qu Zhican engaged in extensive exchanges with leaders from multiple leading pharmaceutical companies, including BeiGene and Hengrui Pharmaceuticals, discussing topics related to anti-tumor drug R&D. These interactions facilitated the exploration of opportunities and potential future collaborations in China's biopharmaceutical industry, further elevating Nanolattix's influence in the field of innovative drug R&D and promoting diversified exchanges and cooperation.
Tag:
recommend News
Share
